Scott Tagawa, MD, on Data Regarding Treatment Patterns and Survival for Metastatic Castration-Sensitive Prostate Cancer
Scott Tagawa, MD, spoke about the implications of the results from his research on treatment patterns of patients with metastatic castration-sensitive prostate cancer, as well as the need for further studies with other data sets.
CancerNetwork® spoke with Scott T. Tagawa, MD, MS, a professor of medicine at Weill Cornell Medicine and physician at NewYork-Presbyterian – Weill Cornell Medical Center, at the 2021 European Society for Medical Oncology (ESMO) Congress about his research into treatment patterns and overall survival in patients with metastatic castration-sensitive prostate cancer from 2006 to 2019.
Of note, although only 20% of patients with metastatic castration-sensitive prostate cancer in this research received intensified therapy, there was a general improvement to length of life. Tagawa suggests intensified therapy, which he described as the most appropriate therapy for the average patient with this disease, should be given to more than just a minority of patients.
Transcription:
This and other population-based or claim-based big databases look at hundreds or thousands of patients up through 2019, even 2020 in the post charted landscape, [and those receiving intensified therapy are] still in the minority of patients. Maybe up to 50%, but a huge chunk of patients are receiving either [androgen deprivation therapy; ADT] alone or ADT plus an old-fashioned nonsteroidal antiandrogen as their frontline therapy. This is despite approximately a 40% improvement in overall survival with those novel drugs being used earlier rather than saved for later. We need to do [more research], not just in this Veterans Health Administration, but in other data sets [including] Medicare and some different commercial insurance plans. I think we need more research into why that’s happening and more education or a combination of both. Providers as well as patients [need assistance] to figure out why patients are not getting the optimal therapy.
Reference
Freedland SJ, Sandin R, Tagawa ST, et al. Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019. Ann Oncol. 2021;32(suppl 5):609P. doi:10.1016/j.annonc.2021.08.1122
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
